Valerio Lucidi1, Thierry Gustot, Christophe Moreno, Vincent Donckier. 1. aLiver Transplant Unit, Department of Abdominal Surgery, Université Libre de Bruxelles (ULB) bLiver Transplant Unit, Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, Hôpital Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Abstract
PURPOSE OF REVIEW: The scarcity of liver grafts requires to optimize the results of transplantation. Extensions and alternatives of liver transplantation have to be regularly evaluated. RECENT FINDINGS: Acute-on-chronic liver failure and severe alcoholic hepatitis may represent potential extensions of transplant indications. In these diseases, selected patients could obtain a significant benefit from liver transplantation, whereas long-term outcomes and global impact on waiting lists remain to be evaluated prospectively. Alternatives to transplantation may be represented by recent progress in the management of hepatitis C and the treatment of hepatocellular carcinoma. In hepatitis C, new drug combinations may improve the disease control, reducing the progression to cirrhosis and also the risk of post-transplant reinfection allowing to anticipate a future decrease in the indications for transplantation and retransplantation in these patients. In hepatocellular carcinoma, thanks to improvements in operative techniques and better identification of prognostic factors of cancer recurrency, surgical resection or radiofrequency destruction could appear now as true alternatives to transplant in highly selected patients. SUMMARY: Before implementation of these potential changes into decisional algorithms for listing and organ allocation, their consequences, either for patient's individual benefit or for global transplant outcomes, should be closely evaluated using objective long-term end points and taking into account the ethical recommendations for organ transplantation.
PURPOSE OF REVIEW: The scarcity of liver grafts requires to optimize the results of transplantation. Extensions and alternatives of liver transplantation have to be regularly evaluated. RECENT FINDINGS: Acute-on-chronic liver failure and severe alcoholic hepatitis may represent potential extensions of transplant indications. In these diseases, selected patients could obtain a significant benefit from liver transplantation, whereas long-term outcomes and global impact on waiting lists remain to be evaluated prospectively. Alternatives to transplantation may be represented by recent progress in the management of hepatitis C and the treatment of hepatocellular carcinoma. In hepatitis C, new drug combinations may improve the disease control, reducing the progression to cirrhosis and also the risk of post-transplant reinfection allowing to anticipate a future decrease in the indications for transplantation and retransplantation in these patients. In hepatocellular carcinoma, thanks to improvements in operative techniques and better identification of prognostic factors of cancer recurrency, surgical resection or radiofrequency destruction could appear now as true alternatives to transplant in highly selected patients. SUMMARY: Before implementation of these potential changes into decisional algorithms for listing and organ allocation, their consequences, either for patient's individual benefit or for global transplant outcomes, should be closely evaluated using objective long-term end points and taking into account the ethical recommendations for organ transplantation.
Authors: Karine Robitaille; Jillian L Rourke; Joanne E McBane; Accalia Fu; Stephen Baird; Qiujiang Du; Tatsuya Kin; A M James Shapiro; Robert A Screaton Journal: J Biol Chem Date: 2016-01-06 Impact factor: 5.157
Authors: Cyrill Wehling; Michael T Dill; Alexander Olkus; Christoph Springfeld; De-Hua Chang; Patrick Naumann; Thomas Longerich; Clemens Kratochwil; Arianeb Mehrabi; Uta Merle; Jan Pfeiffenberger; Christian Rupp; Karl Heinz Weiss; Markus Mieth Journal: J Cancer Res Clin Oncol Date: 2021-02-04 Impact factor: 4.553
Authors: Michał Grąt; Jan Stypułkowski; Waldemar Patkowski; Karolina M Wronka; Emil Bik; Maciej Krasnodębski; Łukasz Masior; Zbigniew Lewandowski; Michał Wasilewicz; Karolina Grąt; Marek Krawczyk; Krzysztof Zieniewicz Journal: Ann Surg Oncol Date: 2017-07-10 Impact factor: 5.344
Authors: Danny van der Helm; Marieke C Barnhoorn; Eveline S M de Jonge-Muller; Ilse Molendijk; Luuk J A C Hawinkels; Minneke J Coenraad; Bart van Hoek; Hein W Verspaget Journal: J Cell Mol Med Date: 2019-06-27 Impact factor: 5.310
Authors: Sofia Karkampouna; Danny van der Helm; Mario Scarpa; Bart van Hoek; Hein W Verspaget; Marie-Jose Goumans; Minneke J Coenraad; Boudewijn P T Kruithof; Marianna Kruithof-de Julio Journal: Cells Date: 2021-11-26 Impact factor: 6.600